IBRX is trading about 4% up now at $8.11 on elevated retail interest and short-squeeze speculation, extending its multi-day rebound while outperforming a negative broader market.
- The stock continues to gain momentum amid ongoing speculation regarding its bladder cancer franchise, despite a lack of fresh company-specific headlines on June 26.
- Wall Street remains highly optimistic with a Strong Buy analyst consensus and a price target of $14.20.